Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF
1934
Date
of Report (Date of Earliest Event Reported):
|
|
November
6, 2007
|
Grant
Life Sciences, Inc.
__________________________________________
(Exact
name of registrant as specified in its charter)
Nevada
______________________
|
000-50133
___________
|
82-0490737
____________
|
(State
or other jurisdiction
|
(Commission
|
(I.R.S.
Employer
|
of
incorporation)
|
File
Number)
|
Identification
No.)
|
|
|
|
1787
East Ft. Union Blvd., Suite 202
Salt
Lake City, Utah
_______________________________
|
|
84121
___________
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
|
|
Registrant’s
telephone number, including area code:
|
|
(801)
733-0878
|
Copies
to:
Gregory
Sichenzia, Esq.
Yoel
Goldfeder, Esq.
Sichenzia
Ross Friedman Ference LLP
1065
Avenue of the Americas
New
York,
New York 10018
Phone:
(212) 930-9700
Fax:
(212) 930-9725
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
1.01 Entry
into a Material Definitive Agreement
On
November 6, 2007 Grant Life Sciences, Inc. (the “Company”) executed
a previously negotiated Exclusive License Agreement with Peter Sveshnikov and
Vsevolod I. Kiselev, citizens of the Russian Federation, pursuant to which
the
Company obtained a license that is exclusive everywhere except Russia and the
independent states that had formerly been part of the Union of Soviet Socialist
Republics. The license relates to certain antigen based technologies that may
be
useful in detecting the presence of certain strains of the human papilloma
virus, which are believed to be causes of cervical cancer. In connection with
the grant of the license the Company agreed to pay Mr. Sveshnikov and Mr.
Kiselev an aggregate initial license fee of $12,000 and 600,000 shares of common
stock of the Company. In addition, Mr. Sveshnikov and Mr. Kiselev will receive
additional royalty payments of 3% of net sales generated from the licensed
technology.
On
November 10, 2007 the Company executed
a previously negotiated Exclusive License Agreement with Alphagenics Diaco
Biotechnologies S.r.l., pursuant to which the Company obtained a license that
is
exclusive for sales in the United States, Taiwan, Hong Kong and China. The
license relates to certain technology that is a DNA based diagnostic that uses
standard molecular diagnostic equipment. In connection with the grant of the
license the Company agreed to pay Alphagenics an initial license fee of $20,000,
up to additional $20,000 upon the completion of the validation of the primers
with respect to the licensed technology and up to $20,000 upon obtaining a
CE
for products based on the licensed technology. In addition, Alphagenics will
receive additional royalty payments equal to the greater of (i) 4% of net sales
generated from the licensed technology, or (ii) $20,000 per year for each
product being sold based on the licensed technology.
Item
3.02 Unregistered
Sales of Equity Securities
The
common stock issued to Peter Sveshnikov and Vsevolod I. Kiselev in connection
with an Exclusive License Agreement described in Item 1.01 was issued in
reliance upon exemption from registration pursuant to Section 4(2) under the
Securities Act of 1933.
Item
9.01 Financial
Statements and Exhibits
Exhibit
No.
|
Description
|
|
|
10.1
|
Exclusive
License Purchase Agreement, dated June __, 2007 by and among the
Company
and Mr. Sveshnikov and Mr. Kiselev
|
10.2
|
Exclusive
License Purchase Agreement, dated July __, 2007 by and among the
Company
and Alphagenics Diaco Biotechnologies
S.r.l.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Grant
Life Sciences, Inc.
|
|
|
|
Date:
November 16, 2007
|
By:
|
/s/Doyle
R. Judd
|
|
Name:
Doyle R. Judd
|
|
Title:
Chief Financial Officer
|